Spago Nanomedical AB Cash Flow Conversion Efficiency

Latest as of December 2025: -0.201x

Spago Nanomedical AB cash flow conversion efficiency. Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has a cash flow conversion efficiency ratio of -0.201x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.19 Million ≈ $-665.71K USD) by net assets (Skr30.75 Million ≈ $3.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Spago Nanomedical AB (2011–2025)

Cash flow conversion efficiency of Spago Nanomedical AB from 2011 to 2025. This chart illustrates how Spago Nanomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Spago Nanomedical AB for real-time trading data and today's change.

Spago Nanomedical AB Cash Flow Conversion Ratio Explained

Spago Nanomedical AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Spago Nanomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Spago Nanomedical AB ranked by their cash flow conversion efficiency. Also see Spago Nanomedical AB (SPAGO) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
4GLOBAL LS-01 F:HS9	N/A
Mobi724 Global Solutions Inc V:MOS	0.023x
Stelrad Group PLC LSE:SRAD	0.108x
DecideAct A/S CO:ACT	-1.946x
Dongwon Systems Corp KO:014825	0.072x
Smiths News PLC LSE:SNWS	2.916x
SATO Technologies Corp V:SATO	-0.336x
Beam Communications Holdings Ltd AU:BCC	0.476x

Annual Cash Flow Conversion Efficiency for Spago Nanomedical AB (2011–2025)

The table below shows the annual cash flow conversion efficiency of Spago Nanomedical AB from 2011 to 2025. Review cash generation quality of Spago Nanomedical AB to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr30.75 Million ≈ $3.31 Million	Skr-28.30 Million ≈ $-3.05 Million	-0.920x	+11.77%
2024-12-31	Skr33.23 Million ≈ $3.58 Million	Skr-34.67 Million ≈ $-3.73 Million	-1.043x	+4.03%
2023-12-31	Skr41.32 Million ≈ $4.45 Million	Skr-44.91 Million ≈ $-4.83 Million	-1.087x	-461.18%
2022-12-31	Skr197.16 Million ≈ $21.22 Million	Skr-38.19 Million ≈ $-4.11 Million	-0.194x	-0.64%
2021-12-31	Skr184.81 Million ≈ $19.89 Million	Skr-35.57 Million ≈ $-3.83 Million	-0.192x	-63.76%
2020-12-31	Skr159.67 Million ≈ $17.18 Million	Skr-18.77 Million ≈ $-2.02 Million	-0.118x	+24.02%
2019-12-31	Skr137.63 Million ≈ $14.81 Million	Skr-21.29 Million ≈ $-2.29 Million	-0.155x	-79.87%
2018-12-31	Skr122.22 Million ≈ $13.15 Million	Skr-10.51 Million ≈ $-1.13 Million	-0.086x	-19.90%
2017-12-31	Skr107.78 Million ≈ $11.60 Million	Skr-7.73 Million ≈ $-831.87K	-0.072x	+34.47%
2016-12-31	Skr71.84 Million ≈ $7.73 Million	Skr-7.86 Million ≈ $-846.18K	-0.109x	-33.92%
2015-12-31	Skr65.41 Million ≈ $7.04 Million	Skr-5.34 Million ≈ $-575.21K	-0.082x	+23.04%
2014-12-31	Skr56.05 Million ≈ $6.03 Million	Skr-5.95 Million ≈ $-640.53K	-0.106x	+47.60%
2013-12-31	Skr38.18 Million ≈ $4.11 Million	Skr-7.74 Million ≈ $-832.62K	-0.203x	-1324.77%
2012-12-31	Skr42.25 Million ≈ $4.55 Million	Skr-601.00K ≈ $-64.68K	-0.014x	+33.80%
2011-12-31	Skr12.84 Million ≈ $1.38 Million	Skr-276.00K ≈ $-29.70K	-0.021x	--

About Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology

Market Cap

$2.39 Million

Skr22.23 Million SEK

Market Cap Rank

#29813 Global

#673 in Sweden

Share Price

Skr0.03

Change (1 day)

-2.33%

52-Week Range

Skr0.03 - Skr0.14

All Time High

Skr19.04